Analyst Price Targets — NEXI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 16, 2022 8:04 am | — | Barclays | $2.00 | $1.19 | Benzinga | Barclays Maintains Overweight on NexImmune, Lowers Price Target to $2 |
| August 16, 2022 7:28 am | — | Raymond James | $3.00 | $1.26 | Benzinga | Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3 |
| June 1, 2022 7:28 am | — | BTIG | $5.00 | $2.28 | Benzinga | BTIG Initiates Coverage On NexImmune with Buy Rating, Announces Price Target of $5 |
Latest News for NEXI
Italy's CDP against selling stake in Nexi, sources say
Italy's state lender Cassa Depositi e Prestiti (CDP) has no plans to divest from payments group Nexi NEXII.Mi, two sources familiar with the matter said on Wednesday.
Graybug Vision (NASDAQ:GRAY) versus NexImmune (OTCMKTS:NEXI) Head-To-Head Review
Risk and Volatility NexImmune has a beta of -2289.14, suggesting that its share price is 229,014% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Profitability This table compares NexImmune and Graybug Vision's net margins, return on
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NEXI.
U.S. House Trading
No House trades found for NEXI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.